- Page 1 and 2: With Contributions of
- Page 3: Turkish Association for Psychopharm
- Page 7 and 8: NOVEMBER 23, 2011 WEDNESDAY TIME HA
- Page 9 and 10: NOVEMBER 25, 2011 FRIDAY AT A GLANC
- Page 11 and 12: 13.30 15.00-16.00 17.30-19.30 17.30
- Page 13 and 14: 09.00-10.30 PS-04: Adult attention
- Page 15 and 16: 20.30-22.30 KC-01: Biostatistics -
- Page 17 and 18: 09.00-10.30 PS-09: From preclinical
- Page 19 and 20: 09.00-10.30 PS-10: Will glutamaterg
- Page 21 and 22: 09.00-10.30 JS-05: Indian Psychiatr
- Page 23 and 24: NOVEMBER 26, 2011 SATURDAY 09.00-10
- Page 25 and 26: NOVEMBER 27, 2011 SUNDAY 09.00-10.3
- Page 27 and 28: Author(s) Abstracts of the Invited
- Page 29 and 30: Author(s) Abstracts of the Invited
- Page 31 and 32: Author(s) Poster Presentation 16 A.
- Page 33 and 34: Author(s) Poster Presentation 60 Ba
- Page 35: Author(s) Poster Presentation 108 O
- Page 38 and 39: Abstracts of the Invited Speakers O
- Page 40 and 41: Abstracts of the Invited Speakers p
- Page 42 and 43: Abstracts of the Invited Speakers D
- Page 44 and 45: Abstracts of the Invited Speakers R
- Page 46 and 47: Abstracts of the Invited Speakers [
- Page 48 and 49: Abstracts of the Invited Speakers H
- Page 50 and 51: Abstracts of the Invited Speakers m
- Page 52 and 53: Abstracts of the Invited Speakers [
- Page 54 and 55:
Abstracts of the Invited Speakers [
- Page 56 and 57:
Abstracts of the Invited Speakers d
- Page 58 and 59:
Abstracts of the Invited Speakers e
- Page 60 and 61:
Abstracts of the Invited Speakers d
- Page 62 and 63:
Abstracts of the Invited Speakers S
- Page 64 and 65:
Abstracts of the Invited Speakers o
- Page 66 and 67:
Abstracts of the Invited Speakers N
- Page 68 and 69:
Abstracts of the Invited Speakers I
- Page 70 and 71:
Abstracts of the Invited Speakers E
- Page 72 and 73:
Abstracts of the Invited Speakers G
- Page 74 and 75:
Abstracts of the Invited Speakers T
- Page 76 and 77:
Abstracts of the Invited Speakers A
- Page 78 and 79:
Abstracts of the Invited Speakers l
- Page 80 and 81:
Abstracts of the Invited Speakers E
- Page 82 and 83:
Abstracts of the Invited Speakers R
- Page 84 and 85:
Abstracts of the Invited Speakers i
- Page 86 and 87:
Abstracts of the Invited Speakers
- Page 88 and 89:
Abstracts of the Invited Speakers R
- Page 90 and 91:
Abstracts of the Invited Speakers A
- Page 92 and 93:
Abstracts of the Invited Speakers P
- Page 94 and 95:
Abstracts of the Invited Speakers [
- Page 96 and 97:
Abstracts of the Invited Speakers R
- Page 98 and 99:
Abstracts of the Invited Speakers O
- Page 100 and 101:
Abstracts of the Invited Speakers T
- Page 102 and 103:
Abstracts of the Invited Speakers e
- Page 104 and 105:
Abstracts of the Invited Speakers o
- Page 106 and 107:
Abstracts of the Invited Speakers S
- Page 108 and 109:
Abstracts of the Invited Speakers C
- Page 110 and 111:
Abstracts of the Invited Speakers [
- Page 112 and 113:
Abstracts of Oral Presentations [SO
- Page 114 and 115:
Abstracts of Oral Presentations Mat
- Page 116 and 117:
Abstracts of Oral Presentations wit
- Page 118 and 119:
Abstracts of Oral Presentations pat
- Page 120 and 121:
Abstracts of Oral Presentations ade
- Page 122 and 123:
Abstracts of Oral Presentations eff
- Page 124 and 125:
Turkish Association for Psychopharm
- Page 126 and 127:
Poster Presentations behavior by ex
- Page 128 and 129:
Poster Presentations [PP-005] Ref.
- Page 130 and 131:
Poster Presentations fulfilling the
- Page 132 and 133:
Poster Presentations [PP-012] Ref.
- Page 134 and 135:
Poster Presentations eating disorde
- Page 136 and 137:
Poster Presentations Conclusion: Th
- Page 138 and 139:
Poster Presentations had no treatme
- Page 140 and 141:
Poster Presentations 80 mg/day (dos
- Page 142 and 143:
Poster Presentations [PP-029] Ref.
- Page 144 and 145:
Poster Presentations [PP-033] Ref.
- Page 146 and 147:
Poster Presentations [PP-037] Ref.
- Page 148 and 149:
Poster Presentations [PP-040] Ref.
- Page 150 and 151:
Poster Presentations [PP-044] Ref.
- Page 152 and 153:
Poster Presentations [PP-046] Ref.
- Page 154 and 155:
Poster Presentations Based on the r
- Page 156 and 157:
Poster Presentations [PP-051] Ref.
- Page 158 and 159:
Poster Presentations [PP-054] Ref.
- Page 160 and 161:
Poster Presentations study, the Cro
- Page 162 and 163:
Poster Presentations [PP-061] Ref.
- Page 164 and 165:
Poster Presentations [PP-064] Ref.
- Page 166 and 167:
Poster Presentations [PP-068] Ref.
- Page 168 and 169:
Poster Presentations motivations fo
- Page 170 and 171:
Poster Presentations [PP-075] Ref.
- Page 172 and 173:
Poster Presentations 4. Şükrü Ka
- Page 174 and 175:
Poster Presentations [PP-081] Ref.
- Page 176 and 177:
Poster Presentations References: 1.
- Page 178 and 179:
Poster Presentations when meeting a
- Page 180 and 181:
Poster Presentations MADRS and HAM-
- Page 182 and 183:
Poster Presentations in terms of co
- Page 184 and 185:
Poster Presentations schizophrenia
- Page 186 and 187:
Poster Presentations ascending dopa
- Page 188 and 189:
Poster Presentations study. The inc
- Page 190 and 191:
Poster Presentations and Spaniards.
- Page 192 and 193:
Poster Presentations patients, and
- Page 194 and 195:
Poster Presentations [PP-110] Ref.
- Page 196 and 197:
Poster Presentations [PP-113] Ref.
- Page 198 and 199:
Poster Presentations [PP-116] Ref.
- Page 200 and 201:
Poster Presentations 22.7%, bipolar
- Page 202 and 203:
Poster Presentations future, we exp
- Page 204 and 205:
Poster Presentations of action, ami
- Page 206 and 207:
Poster Presentations pharmacologica
- Page 208 and 209:
(±)-3-4-methylenedioxymethamphetam
- Page 210 and 211:
Panic symptoms S122 Paroxetine S156
- Page 212 and 213:
Etli T. S162 Evren C. S80, S154, S1
Change language